HHS Secretary Tom Price offered some optimism about a vaccine for addiction, but experts say such it's far from reality.
A global shortage of hepatitis B vaccine has developed as both Merck & Co. and GlaxoSmithKline deal with manufacturing issues.
Here's other vaccine news of note for this week.
Merck KGaA’s MilliporeSigma and Baylor College of Medicine joined together to work on vaccines against neglected diseases.
Meissa Vaccines, a JLABS resident startup, has financial backing from the NIH and a VC firm to help advance its RSV vaccine candidate.
Sanofi Pasteur's new quality testing facility will play a pivotal role in ramping up flu vaccine production.
The FDA is asking for more details about Heplisav-B's postmarketing surveillance plan, but Dynavax executives and analysts said they remain confident.
Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.
Sen. Bernie Sanders is moving in Congress to institute price restrictions on medical products created with U.S. taxpayer dollars.
For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.